Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Respiratory Medicine

Journal Scan / Research · December 30, 2023

Outcomes of Clofazimine vs Rifampicin Use in Patients With Mycobacterium avium Complex Pulmonary Disease



Additional Info

Disclosure statements are available on the authors' profiles:

Clofazimine is a safe and effective alternative for rifampicin in Mycobacterium avium complex pulmonary disease treatment - outcomes of a randomized trial
Chest 2023 Nov 29;[EPub Ahead of Print], SMH Zweijpfenning, R Aarnoutse, MJ Boeree, C Magis-Escurra, R Stemkens, B Geurts, J van Ingen, W Hoefsloot

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading